Bisphosphonates, Denosumab, and Anabolic Agents in the Treatment of Metastatic Bone Disease
Fig. 12.1 The mechanisms of action of bisphosphonates and denosumab with relation to the osteoclast. RANKL: receptor activator of nuclear factor kappa-B ligand The second class of medication consists of…